Improved multiorgan function after prolonged univentricular support

Area of Science:

• Cardiology
• Mechanical Circulatory Support
• Transplantation Medicine

Background:

• Cardiac transplant candidates often present with multiorgan dysfunction, complicating their eligibility and outcomes.
• Left ventricular assist devices (LVADs) are used for end-stage heart failure, but their role in supporting patients with multiorgan dysfunction requires further investigation.

Purpose of the Study:

• To evaluate the effect of prolonged HeartMate LVAD support on end-organ recovery in cardiac transplant candidates with hepatic, pulmonary, and/or renal dysfunction.
• To assess the impact of extended LVAD support on the ultimate outcome of cardiac transplantation.

Main Methods:

• Retrospective analysis of 11 male cardiac transplant candidates with multiorgan dysfunction supported by HeartMate LVAD for over 30 days.
• Evaluation of end-organ function (hepatic, pulmonary, renal) before, during, and after LVAD support.
• Assessment of cardiac transplantation success and patient survival post-transplant.

Main Results:

• All 11 patients underwent successful cardiac transplantation.
• 10 patients survived a mean of 24 months post-transplantation.
• Significant recovery of hepatic (8/9), pulmonary (7/8), and renal (4/6) function was observed during LVAD support.
• One patient requiring hemodialysis and ventilatory support died 7 weeks post-transplantation due to progressive multiorgan failure.

Conclusions:

• Prolonged HeartMate LVAD support is a safe and effective strategy for critically ill cardiac transplant candidates with multiorgan dysfunction.
• This approach allows for reversal of end-organ dysfunction, leading to healthier transplant recipients and improved survival.
• LVAD support in the context of donor shortages can significantly benefit severely ill patients awaiting cardiac transplantation.